
# **Fluoroprolines**

#### Introduction

Fluorinated prolines help improve the lipophilicity, conformation, and dynamic properties of drugs. The first fluoroproline-based drug molecule, danicopan, was approved by the FDA in March 2024.2 Prusogliptin, another drug candidate, has recently shown success in Phase 3 trials.3 In April 2024, Pfizer disclosed the second-generation inhibitor of the SARS-CoV-2 main protease containing trifluoromethylproline. In this molecule, the fluorination enhances the dynamics of the amide rotation, thereby eliciting beneficial effects on bioavailability.4 Enamine offers a broad and remarkably rich collection of fluorine-containing analogues of

Danicopan complement factor D inhibitor
FDA approved 2024, treatment of paroxysmal nocturnal hemoglobinuria
AstraZeneca



Prusogliptin dipeptidyl peptidase-4 inhibitor
Phase 3 trials against type 3 diabetes completed 2024


CSPC Pharm. Group



PF-07817883 second generation SARS-CoV2 main protease inhibitor
Phase 1 clinical trials ongoing
Pfizer

## **Case study**

### We offer: over 100 fluoro- and fluoroalkyl-prolines from stock on 5-10 gram scale.



#### References

P. Mykhailiuk. J. Org. Chem. 2022, 87, 6961.
 J. Wiles et al. Cur. Med. Chem. 2020, 27, 4165.

- W. Wang et al. *Diabetes Obes. Metab.* **2024**, *26*, 1321.
   C. Allerton et al. *J. Med. Chem.* **2024**, *in press*.

